Targeted protein degradation market is projected to grow at an annualized rate of more than 30% till 2030, BY Roots

Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 330+ page report, which features 130+ figures and 145+ tables, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

Key Market Insights

• More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development efforts
• The pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routes
• Although start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domain
• Close to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of development
• A number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development efforts
• Published scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACs
• Foreseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014
• The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companies
• Short term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needs
• As multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions

For more information please visit:

https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

Table of Contents

1. PREFACE

1.1.                   Scope of the Report

1.2.                   Research Methodology

1.3.                   Chapter Outlines

1. 
   EXECUTIVE SUMMARY

1. INTRODUCTION

3.1.                   Context and Background

3.2.                   Concept of Protein Homeostasis

3.3.                   Discovery of the Ubiquitin Proteasome System

3.3.1.                Ubiquitin: Structure and Function

3.3.2.                Fundamentals of the UPS

3.3.3.                Components of the UPS

3.4.                   Key Steps Involved in the UPS

3.4.1.                Ubiquitination: The First Step

3.4.2.                Proteasomal Degradation: The Second Step

3.5.                   Therapeutic Applications of the UPS

3.6.                   Advantages and Challenges Associated with Ubiquitin Enzyme Inhibitors

3.7.                   Targeted Protein Degradation: Enhancing Ubiquitination to Degrade Undruggable Targets

3.7.1.                Brief History of Targeted Protein Degradation

3.8.                   Types of Protein Degraders

3.8.1.                Selective Hormone Receptor Degraders (SHRDs)

3.8.2.                Immumodulatory Imide Drugs (IMiDs)

3.8.3.                PROTACs

3.8.4.                Other Chimeras (ENDTACs, LYTACs and PHOTACs)

3.8.4.1.             Endosome Targeting Chimeras (ENDTACs)

3.8.4.2.             Lysozyme targeting chimeras (LYTACs)

3.8.5.                Specific and Nongenetic Inhibitor-of-Apoptosis Proteins (IAP)-dependent Protein Erasers (SNIPERS)

3.8.6.                Hydrophobic Tag

3.8.7.                Molecular Glues

3.8.8.                DUB Inhibitors  

3.9.                   Growth Drivers and Roadblocks

1. CURRENT MARKET LANDSCAPE

4.1.                   Chapter Overview

4.2.                   Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline

4.2.1.                Analysis by Type of Protein Degrader

4.2.2.                Analysis by Phase of Development

4.2.3.                Analysis by Therapeutic Area

4.2.4.                Analysis by Target Indication

4.2.5.                Analysis by Type of Target Enzyme

4.2.6.                Analysis by Type of Target Protein

4.2.7.                Analysis by Type of Therapy

4.2.8.                Analysis by Route of Administration

4.3.                   Targeted Protein Degradation-based Therapeutics and Technologies: List of Research Tools / Key Technology Platforms

4.4.                   Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape

4.4.1.                Analysis by Year of Establishment

4.4.2.                Analysis by Location of Headquarters

4.4.3.                Analysis by Size of Company

4.4.4.                Analysis by Type of Protein Degrader

1. COMPANY PROFILES

5.1.                   Chapter Overview

5.2.                   Developers with Clinical Candidates

5.2.1.                Radius Health

5.2.1.1.             Company Overview

5.2.1.2.             Targeted Protein Degradation-based Drug Portfolio

5.2.1.2.1.          Product Description: Elacestrant

5.2.1.3.             Recent Developments and Future Outlook

5.2.2.                Celgene

5.2.2.1.             Company Overview

5.2.2.2.             Financial Information

5.2.2.3.             Targeted Protein Degradation-based Drug Portfolio

5.2.2.3.1.          Avadomide (CC-122)

5.2.2.3.2.          Iberdomide (CC-220)

5.2.2.4.             Recent Developments and Future Outlook

5.2.3.                Sanofi Genzyme

5.2.3.1.             Company Overview

5.2.3.2.             Financial Information

5.2.3.3.             Targeted Protein Degradation-based Drug Portfoli